Items tagged with Treatment
TB Alliance partners with PepsiCo to advance the fight for improved medicines for children (post)
October 27, 2016 (LIVERPOOL, ENGLAND) – TB Alliance, a non-profit organization dedicated to developing better and faster cures for tuberculosis (TB), today announced a unique collaboration with food and beverage company PepsiCo designed to improve the treatment for children with TB. Many of today’s TB treatments are very bitter or unpleasant in taste, which when compounded with the long duration of treatment for TB, can lead to low tolerance and poor compliance – especially among children.
Research finds promise in shorter, more effective approaches to treating drug-resistant TB (post)
New research was presented at the 47th Union World Conference on Lung Health:
Tajikistan: Stories from MSF's paediatric TB projects (post)
Delamanid is one of the first new TB medicines in over 50 years, and recently the project team in Dushanbe, Tajikistan's capital, started treating a young TB patient with it. It follows several months of preparations and negotiations with the Ministry of Health and its counterparts.
Early outcomes of decentralized care for rifampicin-resistant TB in Johannesburg, South Africa: an observational cohort study (post)
Abstract
Examining disease characteristics and patterns of weight gain in TB treatment (post)
Tuberculosis (TB), in addition to causing symptoms such as coughing and fever, often results in significant weight loss and lack of appetite. In one study, more than 40% of Los Angeles residents with TB experienced a lack of appetite and more than 44% lost weight. This weight loss—also known as wasting—leads to malnutrition and subsequent impairment of the immune system, and puts the TB sufferer at a much higher risk of dying from the disease. Indeed, TB remains a top cause of death around the globe.
Administering repurposed drug to treat TB via lungs vs orally shows promise (post)
DENVER (Nov. 15, 2016) – Tuberculosis (TB) is responsible for more than 1.8 million deaths each year, according to the World Health Organization, yet there has been little significant improvement in therapies in the past 20 years. This chronic disease is systemic, meaning it affects not only the lungs but also other organs, such as the lymph nodes and spleen. But a promising new treatment may be on the horizon.
‘A huge improvement’: study finds inmates benefit from much shorter TB treatment (post)
Jails and federal prisons in California and elsewhere are adopting new treatment guidelines for latent tuberculosis infection based on research showing that it can be treated effectively during a much shorter period.
Cohort profile: the diabetes-tuberculosis treatment outcome (DITTO) study in Pakistan (post)
Abstract
Clinical trial of BPaMZ regimen will replace Phase 3 STAND trial (post)
NEW YORK (21 December, 2016)—TB Alliance announced, based on positive results from the Phase 2b NC-005 trial, that it will now plan a Phase 3 study to test the BPaMZ (bedaquiline + pretomanid + moxifloxacin + pyrazinamide) regimen. In light of these results, where the BPaMZ regimen appears to be much more promising compared to the PaMZ (pretomanid + moxifloxacin + pyrazinamide) regimen, the STAND trial testing the PaMZ regimen will not be reopened to new patients.
Page 26 of 108 · Total posts: 0
←First 25 26 27 Last→